Merck and AstraZeneca have seen their share prices surge after Bristol-Myers Squibb suffered a major setback with Opdivo in non-small cell lung cancer (NSCLC). BMS announced on Friday that Opdivo ...

Bristol Myers (BMY) Squibb announced that the U.S. FDA granted approval for Opdivo Qvantig injection for subcutaneous use, a combination product of nivolumab co-formulated with recombinant human ...

Opdivo plus Cabometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma. Among patients with ...

Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...